Nozinan (Levomepromazine)

Levomepromazine, the active ingredient in Nozinan, is a phenothiazine antipsychotic presented as a tablet for oral use. It is employed in the management of severe agitation, nausea, and pain, particularly in palliative care settings. GNH USA supplies Nozinan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Nozinan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levomepromazine is a low‑potency phenothiazine that acts on multiple neurotransmitter pathways, providing therapeutic effects in several clinical areas.

- Severe agitation in terminal illness: helps calm patients and reduce distress. - Nausea and vomiting associated with chemotherapy: controls emesis when other agents are insufficient. - Moderate to severe pain in palliative care: enhances analgesia as an adjuvant. - Acute psychotic episodes: reduces psychotic symptoms when higher‑potency agents are not required. - Pre‑operative sedation: provides calming effect before surgery.

Nozinan (levomepromazine/methotrimeprazine) commonly causes strong drowsiness, dry mouth, low blood pressure when standing up, and constipation. Common Side Effects • Sleepiness and fatigue: High levels of sedation, especially during the first few days of treatment. • Anticholinergic effects: Dry mouth, blurred vision, constipation, and difficulty passing urine. • Low blood pressure: Orthostatic hypotension (dizziness or lightheadedness when rising quickly from a sitting or lying position). • Weight gain: Increased risk of metabolic changes and weight changes over time. Serious Side Effects • Extrapyramidal symptoms: Movement issues like tremors, muscle stiffness, restlessness, or shuffling walk. • Heart rhythm changes: QT prolongation and potential irregular heartbeats. • Blood disorders: Agranulocytosis, a severe and dangerous drop in white blood cells causing vulnerability to infections. • Neuroleptic Malignant Syndrome (NMS): A rare, life-threatening condition marked by high fever, severe muscle rigidity, and confusion. • Temperature regulation issues: Trouble adapting to extreme heat or cold, increasing the risk of heat stroke or hypothermia.